Loading
companiesCompany
Olema Pharmaceuticals
Olema Pharmaceuticals is a United States-based biotechnology company running 2 late-stage cancer trials in HR-positive / HER2-negative breast cancer.
Also called: Olema Pharmaceuticals, Inc.
Overview
Olema Pharmaceuticals, based in San Francisco, the United States, is a biotechnology company listed as NASDAQ: OLMA. Olema Oncology is a clinical-stage biopharmaceutical company focused on discovering, developing and commercialising targeted therapies for breast cancer, drawing on expertise in endocrine-driven cancers and nuclear receptors. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3) in HR-positive / HER2-negative breast cancer. The largest, NCT07085767 (Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer), plans to enrol 1000 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
San Francisco, US
Scorecard
All companies#154of 1244 companies, score 39
- approved products +6
- targets +2
- modalities +2
- regions +6
- registry trials +23
1 approved, 0 in phase 3, 0 earlier, 1 targets, 133 registry studies. Formula on the scorecards page.
Type
Biotech · NASDAQ: OLMA
Stage
Public
Website
Founded
2006
ApprovedSmall-molecule CDK4/6 inhibitor
Ribociclib · Kisqali
Ribociclib is the CDK4/6 inhibitor with the most consistent survival benefit, approved for a broad population of early breast cancer patients since 2024.
Similar pages
- PersonDebu Tripathy
Shares Ribociclib, HR-positive / HER2-negative breast cancer.
- TrialStudy of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Shares Ribociclib, HR-positive / HER2-negative breast cancer.
- PairingCDK4/6 inhibitor + endocrine therapy
Shares Ribociclib, HR-positive / HER2-negative breast cancer.
- TrialA Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Shares Ribociclib, HR-positive / HER2-negative breast cancer.
- TrialA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Shares Ribociclib, HR-positive / HER2-negative breast cancer.
- TrialSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Shares Ribociclib, HR-positive / HER2-negative breast cancer.
- TrialPhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Shares Ribociclib, HR-positive / HER2-negative breast cancer.
- PersonGabriel N. Hortobagyi
Shares Ribociclib, HR-positive / HER2-negative breast cancer.